Synta Pharmaceuticals Corp.’s (SNTA) share price has entered into oversold territory with an RSI value of 26.6. The Zacks Consensus Estimate on Synta Pharmaceuticals Corp.’s earnings for the full year period has loss of 0.02 cents over the past two months to $-1.18 per share. Currently, Synta Pharmaceuticals Corp. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (SNTA) after its recent drop.
SYNTA PHARMACEUTICALS INC (SNTA): Free Stock Analysis Report
Zacks Investment Research
- Health Care Industry
- Investment & Company Information